Efficacy and safety of simultaneous combined Zephyr and Spiration valve therapy in patients with advanced pulmonary emphysema

RECOMMENDED

Emphysema

Outcome and safety 90 days after combined airway valve treatment of the right upper and middle lobes in patients with severe pulmonary emphysema

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Dittrich AS, De Pace CC, Brock JM, Trudzinski F, Heussel CP, Eberhardt R, Herth FJF, Kontogianni K

doi: 10.1186/s12931-024-03069-6

RECOMMENDED

Pulmonary Hypertension

Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Heart Lung Transplant

Rosenkranz S, Ghofrani HA, Hoeper MM, Langleben D, Hegab S, Rahner C, Richard JF, McLaughlin VV

doi: 10.1016/j.healun.2024.08.018

Lung Cancer

Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis

Clin Lung Cancer

Zeng Z, Feng S, Gao T, Chen C, Chen J, Chen J, Lian Y

doi: 10.1016/j.cllc.2025.04.010

RECOMMENDED

Lung Cancer

Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Kakiuchi Y, Saruwatari K, Murotani K, Tokito T, Iriki T, Iwakawa J, Sakata Y, Shingu N, Saeki S, Inaba M, Takaki A, Misono S, Suetsugu T, Azuma K, Mizuno K, Sakagami T

doi: 10.1016/j.cllc.2024.07.001

RECOMMENDED

Pulmonary Hypertension

Advanced Management of Patients Undergoing Transcatheter Treatment for Pulmonary Embolism: Evidence-Based Strategies for Optimized Patient Care

★ 1 Recommended by Dr Martin Frey, Faculty Member

J Clin Med

Costa F, Jurado-Román A, Carciotto G, Becerra-Munoz V, Márquez DT, Götzinger F, Cerrato E, Misra S, Spissu M, Pavani M, Mennuni M, Chinchilla FC, Dominguez-Franco A, Muñoz-Garcia A, Navarrete RS, Varbella F, Salinas-Sanguino P, Secemsky EA, Mahfoud F, Micari A, Alonso-Briales JH, Navarro MJ

doi: 10.3390/jcm13247780

RECOMMENDED

AsthmaFurther Publications

Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Park HS, Lee J, Kim H, Woo SD

doi: 10.1186/s12931-024-03084-7

RECOMMENDED

COPD

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS, COURSE study investigators

doi: 10.1016/S2213-2600(24)00324-2

Lung Cancer

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study

Lancet Respir Med

Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, Bi M, Zhao Y, Yao W, Yu H, Wang K, Zhao W, Sun M, Zhang L, He Z, Lin Y, Shi J, Zhu B, Wang L, Pan Y, Shi H, Sun S, Wen M, Zhou R, Guo S, Han Z, Yi T, Zhang H, Cang S, Yu Z, Zhong D, Cui J, Fang J, Gao J, Li M, Ma R, Jiang M, Qin J, Shu Y, Ye F, Hu S, Li W, Lu H, Yang M, Yi S, Zhang Y, Fan Y, Ji H, Liu Z, Wang H, Zhou X, Zhang D, Peng J, Shen H, Gao F, Wang T, Zhou A

doi: 10.1016/S2213-2600(24)00417-X

Pulmonary Fibrosis

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Adv Ther

Inoue Y, Ogura T, Azuma A, Kondoh Y, Homma S, Muraishi K, Ikeda R, Ochiai K, Sugiyama Y, Nukiwa T

doi: 10.1007/s12325-024-03079-2

Related content

Outcome and safety 90 days after combined airway valve treatment of the right upper and middle lobes in patients with severe pulmonary emphysema

Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials

Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis

Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study

Advanced Management of Patients Undergoing Transcatheter Treatment for Pulmonary Embolism: Evidence-Based Strategies for Optimized Patient Care

Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan